OpGen (NASDAQ: OPGN) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare OpGen to similar businesses based on the strength of its institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Institutional and Insider Ownership

11.8% of OpGen shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 31.8% of OpGen shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares OpGen and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
OpGen $4.03 million -$19.16 million -0.39
OpGen Competitors $217.40 million -$39.57 million -16.01

OpGen’s competitors have higher revenue, but lower earnings than OpGen. OpGen is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for OpGen and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OpGen 0 0 2 0 3.00
OpGen Competitors 565 2470 6680 134 2.65

OpGen currently has a consensus price target of $1.00, indicating a potential upside of 402.51%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.53%. Given OpGen’s stronger consensus rating and higher possible upside, research analysts plainly believe OpGen is more favorable than its competitors.

Profitability

This table compares OpGen and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OpGen -533.47% -1,289.51% -234.78%
OpGen Competitors -4,607.57% -480.30% -43.17%

Summary

OpGen beats its competitors on 7 of the 12 factors compared.

OpGen Company Profile

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with Analyst Ratings Network's FREE daily email newsletter.